

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 8 November, 2024

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI – 400 051.

Dear Sir/Madam,

Sub: Analysts/Investors Call

Ref: Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q2 and H1 - FY25 Earnings Call for the quarter and half year ended September 30 2024. Conference Call to be held on Thursday, November 14, 2024, at 5:30 PM IST.

Thanking you

For Shilpa Medicare Limited,

Ritu Tiwary
Company Secretary & Compliance Officer

Shilpa Medicare Limited

Q2 and H1 FY25 Earnings Call

November 14, 2024, at 5:30 PM

Mumbai, November 8, 2024: Shilpa Medicare Ltd. (BSE- 530549, NSE- SHILPAMED, ISIN: INE790G01031), will announce its financial results for the quarter and half year ended September 30, 2024, **on Wednesday, November 13, 2024**. Following the announcement, the management of the Company will host an **Earnings Call on Thursday, November 14, 2024, at 5:30 PM IST**.

| Details of Earnings Conference Call | |
|--|---|
| Day/Date | Thursday, November 14, 2024 |
| Time (IST) | 5:30 PM |
| Universal Access | +91 22 6280 1130 +91 22 7115 8031 |
| <i>The number listed above is universally accessible from all networks and all countries</i> | |
| International Toll-Free Numbers | |
| USA | 18667462133 |
| UK | 08081011573 |
| Singapore | 8001012045 |
| Hong Kong | 800964448 |
| DiamondPass™ Link | Click Here to join with DiamondPass™ (No Wait Time) |
| Management Representation: | |
| Mr. Keshav Bhutada, Executive Director (SPLL) | |
| Mr. Alpesh Dalal, Chief Financial Officer | |
| <i>Participants are requested to dial-in 10 minutes before the scheduled time</i> | |

About Shilpa Medicare Limited (SML):

Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio.

The company also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

For further details, please get in touch with:

Shilpa Medicare Ltd

Mr. Dilip Kankani

B: + 91 8532 238704

E: dilipkankani@vbshilpa.com

EY IR:

Ms. Runjhun Jain / Ms. Sneha Salián

M: +91-98207 20993/ +91-98194 30437

E: runjhun.jain1@in.ey.com /

sneha2.salian@in.ey.com